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Clostridium difficile infection in children:
a retrospective cohort study
Kevin L Schwartz1*, Ilyse Darwish2, Susan E Richardson3, Michael R Mulvey4 and Nisha Thampi1,5Abstract
Background: Clostridium difficile infection (CDI) is the most common cause of health care–associated diarrhea in
children and adults. Although serious complications of CDI have been reported to be increasing in adults, this trend
has not yet been demonstrated in children. The purpose of this study was to examine the features of CDI in a
pediatric population, with special attention to the occurrence of CDI-related severe outcomes.
Methods: A chart review was conducted for patients with C. difficile infection detected by cytotoxin assay between
August, 2008 and July, 2012. Basic demographics, mode of acquisition (nosocomial versus community), laboratory
and clinical features, treatment, and outcome data were collected. Pulsed-field gel electrophoresis and polymerase
chain reaction detection of toxin A (tcdA), toxin B (tcdB), binary toxin (cdtB) and tcdC genes were performed on
isolates from nosocomial cases by the National Microbiology Laboratory, Winnipeg, Manitoba.
Results: Ninety percent of children with CDI experienced resolution of symptoms by 30 days after disease onset
and 2% experienced a severe outcome. There were no cases where colectomy was performed for CDI, and only
one case where CDI contributed to death. Various combinations of clinical and laboratory features were not
predictive of a severe outcome. Seventy-four percent of cases were nosocomial-associated. Among all cultured
strains, the NAP4 strain occurred most frequently (24%), followed by NAP1 (11%). There was no association between
strain type and clinical outcome; however, relapses were significantly more frequent in NAP4-infected children.
Conclusions: Severe outcomes due to CDI are uncommon in children compared to adults. Further prospective
pediatric studies on CDI in community and hospital settings are required to better understand risk factors, optimal
treatment and the significance of NAP4 in pediatric CDI.
Keywords: Clostridium difficile, North American pulsed-field type, Pediatrics, ChildBackground
Clostridium difficile is the most common cause of diar-
rhea in hospitalized children [1,2], usually associated
with antibiotic use. Over the last decade incidence rates
of nosocomial C. difficile infection (CDI) in adults have
increased in most geographical locations [3]. Accom-
panying the rise in incidence has been an increase in the
rate of colectomies performed for CDI, length of stay
(LOS), hospital costs, and attributable mortality [4-6] as-
sociated with C. difficile infection. This rise in severity* Correspondence: Kevin.schwartz@sickkids.ca
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stated.has been largely linked to the emergence of the North
American pulse-field gel electrophoresis type 1, restric-
tion endonuclease analysis group BI, polymerase chain
reaction (PCR) ribotype 027 (NAP1/BI/027) strain [5,7].
The epidemiology of pediatric C. difficile has been less
well characterized, however recent data suggest a rise in
the incidence rate of nosocomial CDI, from 4.4 to 6.5
cases per 10,000 patient-days in the United States (US)
between 2001 and 2006 [8]. Other authors have docu-
mented a rise in incidence of 9% [9] to 14% [10] per
year. A similar rise in community-associated cases has
also been observed [11,12]. One U.S. pediatric study
showed an increase from 2.2 to 23.5 cases of CDI per
100,000 persons over the previous two decades [12].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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not been an increase in disease severity as measured by
LOS, colectomy rate, and mortality rate [9,10,13]. How-
ever, longer LOS and higher colectomy rates occur in
children with CDI compared to non-CDI hospitalized
controls matched for demographics and comorbid con-
ditions [9].
Given our clinical observation that CDI in children is
rarely associated with a severe clinical outcome, as com-
pared to adults, we set out to characterize severe out-
comes and CDI-associated complications at a pediatric
hospital providing primary (self-referred cases) to ter-
tiary (regional referral center) care to a large population
base.
Methods
A retrospective chart review was conducted at a 370-bed
pediatric academic hospital in Toronto, Canada. Our in-
stitution services a varied pediatric population, ranging
from the well child to the immune compromised child.
This hospital performs 110 autologous and allogeneic
hematopoietic stem cell transplants annually, in addition
to solid organ transplants (liver, kidney, heart, lung, and
small bowel). Patients from 1 through 17 years of age
with a positive C. difficile cytotoxin assay in the stool be-
tween August 1, 2008 and July 31, 2012, were identified
from microbiology records. Our laboratory restricts test-
ing to children greater than one year of age.
Charts from the first presentation of CDI were re-
viewed and information related to basic demographics,
laboratory and clinical features, C. difficile-directed anti-
biotic use, and clinical outcome were extracted. Clinical
and laboratory features included stool frequency and
consistency. Clinically-based definitions for diarrhea were
modified from the Canadian Nosocomial Infection Sur-
veillance Program (CNISP) definitions [14] for use in chil-
dren, and were defined as: severe: 6 or more watery stools
in a 36-hour period; moderate: greater than 2 loose stools,
but not meeting the definition for severe; mild: a change
in stooling pattern to 1–2 loose stools daily; no diarrhea
or not documented. Risk factors for severity of infection
were defined as: presence of blood in stool, fever ≥38°C,
leukocytosis ≥15×109/L, hypoalbuminemia ≤25 g/L, and
creatinine above the normal limit according to age [15]. A
severe outcome was defined as the need for intensive care
unit (ICU) admission, colectomy, or death within 30 days
of a positive C. difficile cytotoxin assay [14]. Each severe
outcome was evaluated and designated as unrelated to,
contributing to, or a direct effect of CDI by authors, KS
and ID, and confirmed by two other investigators, SR and
NT. Other clinical outcomes assessed at 30 days after dis-
ease onset included date of discharge from hospital, pres-
ence or absence of symptoms, or ongoing treatment
directed at C. difficile. Relapse was defined as recurrenceof previously resolved symptoms with a positive test for C.
difficile, two or more weeks from the onset of the initial
episode, whether or not the patient had been treated with
antibiotics. If patients required re-admission for relapse,
their charts were reviewed to capture any severe outcome,
however, each patient was only included in the study once.
C. difficile was categorized as community-associated if
symptoms developed within 72 hours of admission, with
no hospitalization in the previous 8 weeks, consistent with
CNISP [14]. This study was approved by the Quality Im-
provement Review Board at the Hospital for Sick Children,
Toronto, Canada. Individual patient/guardian consent was
not obtained.
Statistically significant differences between groups
were assessed by the chi-squared test or Fisher’s exact
test, where appropriate. A p-value <0.05 was considered
statistically significant. The incidence of nosocomial-
associated disease was calculated to be the number of
cases of CDI per 10,000 hospital inpatient days.Laboratory methods
C. difficile toxin was detected using a Vero cell cytotox-
icity assay as previously described [16]. Stools from
nosocomial CDI cases were frozen at -80°C, and referred
to the National Microbiology Laboratory, Winnipeg,
Canada, for culture, typing and further analysis as part
of a larger study through CNISP [14]. Isolates were
typed using pulsed-field gel electrophoresis (PFGE) to
determine North American pulsed-field (NAP) types,
and PCR to detect the presence of genes for toxin A and
B (tcdA and tcdB, respectively), binary toxin (cdtB), and
size alterations of the toxin gene regulator (tcdC) [7].
Minimum inhibitory concentrations of each strain to a
panel of antibiotics (metronidazole, clindamycin, vanco-
mycin, rifampin, moxifloxacin, tigecycline) were deter-
mined by the Etest method [17].Results
From August 1, 2008 to July 31, 2012 there were 5751
stool samples tested for C. difficile toxin by cytotoxin
assay, with 435 positives and 299 individual patients ana-
lyzed. During the study period, the nosocomial CDI rate
was 8.3 per 10,000 patient days. This trend did not change
in any age group or year over the 4-year study period.
Hospital-associated infections accounted for 222 (74%) of
cases, and 77 (26%) were community-associated.
Demographic, clinical and laboratory findings are sum-
marized in Table 1. Males accounted for 58% of the total
number of cases and the median age was 6.5 years
(interquartile range, 3–13 years). Nearly 40% of cases
had an underlying malignancy, a third of which had
undergone hematopoietic stem cell transplant (HSCT).
Inflammatory bowel disease (IBD) comprised 10% of
Table 1 Characteristics of 299 children with Clostridium
difficile cytotoxin detected in stool
Category n (%)
Demographic Characteristics





Underlying medical condition 206 (69)
Malignancy 78 (26)
Hematopoietic stem cell transplant 40 (13)
Chromosomal/genetic syndrome 33 (11)
Inflammatory bowel disease 31 (10)
Solid organ transplant 24 (8)
Cystic fibrosis 8 (3)
Other* 8 (3)
Congenital heart disease 6 (2)
Hirschsprung’s disease 2 (1)
Hospital-associated CDI 222 (74)
Clinical features
Fever≥ 38.0°C 140 (47)
Abdominal pain 106 (35)






None/no documentation 21 (7)
Laboratory features
White blood cells ≥ 15 × 109/L 64 (21)
Creatinine > normal level (adjusted for age) 40 (13)
Albumin≤ 25 g/L 45 (15)
CDI-directed antimicrobial therapy 240 (80)
†Median (interquartile range).
*Other underlying medical conditions: Aplastic anemia (4), Juvenile idiopathic
arthritis (3), and biliary atresia (1).
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community-associated disease.
Mild, moderate, or severe diarrhea was seen in 22%,
44%, and 27% of children with CDI, respectively
(Table 1). Clinical severity was similar in community-
and nosocomial-associated cases. Two or more risk fac-
tors for severe disease were noted among 89 children
(30%). However, these cases were not significantly asso-
ciated with severe outcomes, compared to those who
had less than two risk factors (Table 2). The relapse ratewas 17% overall. Eighty per cent of children with CD
toxin in their stool received antibiotic therapy directed
at CDI, usually metronidazole.
At thirty days following the onset of symptoms, 89%
of patients were discharged or had resolution of symp-
toms, 2% had a severe outcome (5 ICU admissions, 1
CDI-associated death), and 9% had ongoing diarrhea or
were still receiving treatment, more than half of whom
had underlying IBD or malignancy (Table 2). The 5 chil-
dren admitted to the ICU required management of ileus,
upper gastrointestinal bleeding, or septic shock. Colec-
tomy was not performed for any reason on any patient
in the cohort during the study period.
There was one death during the study period, to which
CDI was deemed to contribute. This was in a 7-year-old
child following HSCT who developed severe diarrhea
followed by septic shock and ileus. He was admitted to
the ICU, grew Enterobacter cloacae from his blood with
C. difficile toxin identified in the stool on the same day.
The child was unstable and no surgical intervention was
considered. Within 48 hours of admission to ICU the
child died from severe sepsis. The primary cause of
death was felt to be gram-negative sepsis with CDI con-
tributing to death.
PFGE data were available for 90 cultured C. difficile
isolates from 129 nosocomial cases submitted to CNISP
between August 1, 2008 and July 31, 2012 (Table 3).
Thirty-four isolates (38%) did not have a fingerprint pat-
tern that fell into a NAP cluster designation. NAP4 was
the most common strain type (n = 22, 24%), followed by
NAP1 (n = 10, 11%). Relapse rates were 41% and 15% for
NAP4 and non-NAP4 strains, respectively, which was
statistically significant (p = 0.009). There were no signifi-
cant differences in symptom severity, the need for ICU
admission, surgical consultation, or death based on
strain type. Of the 90 isolates, all had toxin A and B de-
tected by PCR. Binary toxin was detected in 16 (18%) of
90 isolates, and in 9 out of 10 of the NAP1 strains. The
tcdC gene was detected in all isolates; all NAP1 strains
had the characteristic 18 bp deletion. All isolates were
susceptible to metronidazole, vancomycin, rifampin, and
tigecycline. In addition, 60% of isolates were intermedi-
ate or resistant to clindamycin, and 9% were intermedi-
ate or resistant to moxifloxacin. Of the NAP1 and NAP4
strains, 30% and 9% were intermediate or resistant to
moxifloxacin, respectively (Table 3).
Discussion
In this study, we describe a cohort of 299 hospitalized
children, 1–17 years of age, with C. difficile infection at a
large tertiary care centre. Three quarters of the cases were
nosocomial in origin and occurred among children with
chronic underlying medical conditions, many of whom
had compromised immune systems or inflammatory
Table 2 Outcomes of 299 children with C. difficile infection









Discharged or resolution of symptoms 269 (90) 77 (29) 211 (71) 22 (8) 107 (40)
Ongoing diarrhea and/or treatment 28 (9) 12 (43) 27 (96) 9 (32)* 7 (25)
ICU admission 5 (2) 3 (60) 5 (100) 0 (0) 4 (80)
Death‡ 1 (0.3) 1 (100) 1 (100) 0 (0) 1 (100)
Relapse 52 (17) 13 (25) 43 (83) 5 (10) 24 (21)
*Significant at p < 0.05. Children with IBD and CDI were more likely to have ongoing diarrhea compared to children without IBD by Chi-squared test. No other
significant differences were identified.
†Risk factors include fever >38°C, bloody stool, hypoalbuminemia ≤25 g/L, leukocytosis ≥15×109/L, and renal dysfunction defined as creatinine above normal
limits for age. There were no significant differences in outcomes (p > 0.05) in children with and without 2 or more risk factors.
‡Death to which CDI contributed.
CDI = C. difficile infection; ICU = intensive care unit; IBD = inflammatory bowel disease; BMT = bone marrow transplant.
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lated to CDI occurred in only 2% of our cases, despite the
presence of serious underlying illness in 50% of cases. Col-
ectomy was not performed in any child, few were admit-
ted to the ICU, and CDI was felt to contribute to only one
death in the cohort. Most children fully recovered from
their illness by 30 days after disease onset, irrespective of
whether the illness was nosocomial or community-
associated, the severity of illness, or treatment received.
Of the 9% with ongoing diarrhea, more than half had
underlying IBD or malignancy, which may have con-
founded the determination of etiology of persistent symp-
toms. We also observed a high prevalence of NAP4
among typeable isolates in our pediatric cohort, which is
in contrast to the high prevalence of NAP1 strains in
adults from similar geographic areas [18].
The incidence rate of nosocomial CDI (8.3 cases per
10,000 patient days) did not change significantly over
the study period. This is in contrast to studies of American
children, in which a 9% yearly rise in incidence of CDI has
been reported [8,19].
The severity and outcome of CDI in children is poorly
understood compared to adults. Pediatric data compar-
ing children with CDI to matched controls have shown
longer LOS, higher hospital costs, and higher rates of
colectomy [8,9]. Administrative data sets including thou-
sands of children with CDI have indicated colectomyTable 3 North American Pulsed-field types in 90 children with
for testing
Strain Total, n (%) Relapse, n (%)
NAP4 22 (24) 9 (41)*
NAP1 10 (11) 1 (10)
Other NAP type‡ 24 (27) 2 (8)
No NAP type 34 (38) 7 (21)
Total 90 19 (21)
*p = 0.009.
†Severe outcome = ICU transfer, colectomy, or death within 30 days of a positive C.
‡Other NAP = NAP10 (n = 4), NAP11 (n = 8), NAP6 (n = 3), NAP7 (n = 2), NAP2 (n = 3),rates ranging from 0.35 to 1.2% [8,9,20]. Adjusted for co-
morbidities, children with CDI in a large database study
had a 1.36 fold increased risk of undergoing colectomy
compared to controls without CDI [9]. One of the chal-
lenges with such administrative database studies is ascer-
taining the reasons for colectomy. It is possible that a
number of the colectomies were performed for under-
lying IBD or for another clinical indication. If C. difficile
is detected during an IBD exacerbation, it has been
shown to be a marker for severity and increased in-
hospital mortality [21]. However, among both pediatric
patients with IBD and non-IBD controls, toxigenic C.
difficile is frequently detected irrespective of symptoms
[22]. As a result, some of the complications seen in
pediatric CDI are possibly accounted for by underlying
comorbidities.
In our study, a small number of children (2%) suffered a
severe outcome. This is in marked contrast to adult CDI,
where severe outcomes have been reported in 8–20%
[7,23] and C. difficile-attributed or associated mortality
has been reported in approximately 5–9% of cases, espe-
cially among those harboring the NAP1 strain [4,7,24,25].
In contrast to reports of adult CDI, NAP4 was the
most common strain type in our pediatric cohort, ac-
counting for 24% of nosocomial isolates. NAP1 was the
second most common at 11%. Similar rates of NAP1
have recently been reported among children in the USnosocomial C. difficile infection and organism available
Severe outcome†, n (%) Moxifloxacin susceptible, n (%)
0 (0) 20 (91)
1 (10) 7 (70)
0 (0) 22 (92)
2 (6) 33 (97)
3 (3) 82 (91)
difficile cytotoxin assay.
NAP8 (n = 2), NAP12 (n = 2).
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toward an increasing incidence of NAP1 among adults
with CDI, from 28.5% (2005) to 43.5% (2010), with the
highest prevalence of 51% in eastern Canada [18].
Neither NAP4 nor NAP1 was associated with more se-
vere illness in our cohort, although relapse rate was sig-
nificantly higher in patients with NAP4 compared to
non-NAP4 strains. However, we could not determine
whether the relapses were caused by the same strain. In
contrast, a large Canadian study of adult CDI showed
that severe outcomes occurred significantly more fre-
quently in patients between the ages of 60 and 90 years
of age who were infected with the NAP1 strain, com-
pared to other strains [7]. However, the importance of
the NAP1 strain in severity of disease has been chal-
lenged by case–control studies that were unable to dem-
onstrate any difference in disease severity with NAP1
infection compared to other strains [23]. From our data
we were unable to associate the high prevalence of
NAP4 with a cluster of cases, limited in time or geog-
raphy. As this is the first report of NAP4 predominance
in pediatric CDI, further investigation will be necessary
to elucidate the role of NAP4 in disease in children and
to better determine associations with disease relapse.
Another important difference between children and
adults in Canada is the rate of moxifloxacin susceptibil-
ity. In our cohort 91% of all strains (91% of NAP4 and
70% of NAP1 strains) were susceptible to moxifloxacin.
In contrast, only 33% and 17% of all strains, and NAP1
strains, respectively, were susceptible to moxifloxacin in
a predominantly adult Canadian study [14]. It should
also be noted that the PFGE subtype of the NAP1 isolates
identified in this study were not the common NAP1 PFGE
subtype observed across Canada which is typically
moxifloxacin-resistant. The lower use of fluoroquinolones
in pediatrics could be driving this observation.
There are no established pediatric predictors for dis-
ease severity. Our study demonstrated that proven adult
risk factors of fever, bloody stools, leukocytosis, renal
dysfunction, and hypoalbuminemia were common in our
population. These so-called risk factors were not associ-
ated with disease severity or complications and were
likely related to the underlying conditions of malignancy
and IBD. This finding has been identified by other au-
thors who have proposed new criteria for pediatric CDI,
which require further study and validation [28].
Most infections were associated with current or previ-
ous hospitalization, and occurred predominantly among
children with underlying immunocompromising condi-
tions. Community-associated infection was observed in
26% of children, more than half of whom had IBD.
These findings represent our population of children with
high rates of comorbid conditions. Community-
associated disease is harder to assess in this setting andwould require a community-based study to determine
incidence. A recent population-based study in the U.S.
identified that 75% of pediatric CDI was community-
associated, suggesting that hospital-based incidence rates
likely underestimate true CDI rates in children [12].
However, in our study, we were unlikely to miss compli-
cated cases, as we expect most of these children to have
been referred to our centre from the community. Given the
lack of data and the increasing incidence of community-
associated disease [11,12], future pediatric CDI research
should focus on this issue.
Our study has several limitations and biases inherent
to retrospective reviews. Findings were limited to infor-
mation available from the charts. Almost 30% of chil-
dren in this study would not have met adult criteria for
disease by having less than 3 loose stools per day. How-
ever as there are no well-defined pediatric criteria for
significant disease and, as the goal of this study was to
detect any CDI related complication, we included all
children with C. difficile detected in stools sent for clin-
ical reasons. The cytotoxic assay is very specific and cor-
relates well with disease but lacks sensitivity compared
to PCR or to cytotoxic culture (toxin assay on culture
positive C. difficile). Therefore it is possible some cases
were missed. Sixty percent of nosocomial isolates were
sent for reference typing, but in only half of these C. dif-
ficile was recovered on culture, resulting in a complete
clinical with strain-typing dataset of 30% of the included
children in the study. Antibiotic exposure data was miss-
ing for too many patients from which to draw meaningful
conclusions regarding specific risk factors, particularly in
community-associated disease. This will be important data
to collect in future prospective studies on CDI in children.
Our study has a number of strengths. We were able to
show the relationship of pediatric CDI with generally be-
nign clinical outcomes. Furthermore since our hospital
excludes testing in infants less than 1 year of age and
our laboratory was utilizing a cytotoxin assay during the
study period, we have confidence that these cases had a
high probability of representing true infection as op-
posed to colonization.Conclusions
This study describes a population of 299 children with
nosocomial and community-associated CDI over a four-
year period. Children had a much lower rate of severe
complications of CDI than that reported in adults. This
is the first report to describe NAP4 as the predominant
nosocomial strain type in a pediatric institution, and its
association with relapse.Competing interest
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